AbbVie Stock (ABBV) Today: Price, Dividend Hike, Pipeline Catalysts and 2025–2026 Outlook
AbbVie closed at $226.08 on December 5, down 1.15% and about 7% below its October record high. Q3 2025 revenue rose 9.1% to $15.78 billion, with Skyrizi sales up 47% and Humira down over 55%. Adjusted EPS of $1.86 beat estimates, prompting the company to raise its full-year outlook. Market cap stands near $400 billion.